A Distributed, Collaborative Intelligent Agent System Approach for Proactive Postmarketing Drug Safety Surveillance

被引:12
|
作者
Ji, Yanqing [1 ]
Ying, Hao [2 ]
Farber, Margo S. [3 ]
Yen, John [4 ]
Dews, Peter [5 ]
Miller, Richard E. [6 ]
Massanari, R. Michael [7 ]
机构
[1] Gonzaga Univ, Dept Elect & Comp Engn, Spokane, WA 99258 USA
[2] Wayne State Univ, Dept Elect & Comp Engn, Detroit, MI 48202 USA
[3] Detroit Med Ctr, Detroit, MI 48201 USA
[4] Penn State Univ, Coll Informat Sci & Technol, University Pk, PA 16802 USA
[5] Wayne State Univ, Dept Med, Detroit, MI 48201 USA
[6] John D Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA
[7] Res Crit Junctures Inst, Bellingham, WA 98225 USA
基金
美国国家卫生研究院;
关键词
Adverse drug reactions (ADR); fuzzy logic; intelligent agents; postmarketing surveillance; recognition-primed decision (RPD) model; SIGNAL GENERATION; ADVERSE; PHARMACOVIGILANCE;
D O I
10.1109/TITB.2009.2037007
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Discovering unknown adverse drug reactions (ADRs) in postmarketing surveillance as early as possible is of great importance. The current approach to postmarketing surveillance primarily relies on spontaneous reporting. It is a passive surveillance system and limited by gross underreporting (< 10% reporting rate), latency, and inconsistent reporting. We propose a novel team-based intelligent agent software system approach for proactively monitoring and detecting potential ADRs of interest using electronic patient records. We designed such a system and named it ADR-Monitor. The intelligent agents, operating on computers located in different places, are capable of continuously and autonomously collaborating with each other and assisting the human users (e. g., the food and drug administration (FDA), drug safety professionals, and physicians). The agents should enhance current systems and accelerate early ADR identification. To evaluate the performance of the ADRMonitor with respect to the current spontaneous reporting approach, we conducted simulation experiments on identification of ADR signal pairs (i.e., potential links between drugs and apparent adverse reactions) under various conditions. The experiments involved over 275 000 simulated patients created on the basis of more than 1000 real patients treated by the drug cisapride that was on the market for seven years until its withdrawal by the FDA in 2000 due to serious ADRs. Healthcare professionals utilizing the spontaneous reporting approach and the ADRMonitor were separately simulated by decision-making models derived from a general cognitive decision model called fuzzy recognition-primed decision (RPD) model that we recently developed. The quantitative simulation results show that 1) the number of true ADR signal pairs detected by the ADRMonitor is 6.6 times higher than that by the spontaneous reporting strategy; 2) the ADR detection rate of the ADRMonitor agents with even moderate decision-making skills is five times higher than that of spontaneous reporting; and 3) as the number of patient cases increases, ADRs could be detected significantly earlier by the ADRMonitor.
引用
收藏
页码:826 / 837
页数:12
相关论文
共 50 条
  • [1] Distributed, collaborative intelligent agents for proactive post-marketing drug safety surveillance
    Ji, Yanqing
    Ying, Hao
    Farber, Margo S.
    Yen, John
    Dews, Peter
    Miller, Richard E.
    Massanari, R. Michael
    [J]. NAFIPS 2007 - 2007 ANNUAL MEETING OF THE NORTH AMERICAN FUZZY INFORMATION PROCESSING SOCIETY, 2007, : 158 - +
  • [2] Postmarketing surveillance for drug safety
    Holden, WL
    Scarazzini, LJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (05) : 503 - 503
  • [3] A team agent approach to postmarketing surveillance of adverse drug reactions
    Ji, Yanqing
    Ying, Hao
    Barth-Jones, Daniel C.
    Yen, John
    Zhu, Shizhuo
    Miller, Richard E.
    Massanari, R. Michael
    [J]. 2005 27TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-7, 2005, : 6969 - 6972
  • [4] Postmarketing surveillance for drug safety - Reply
    Griffin, MR
    Stein, CM
    Ray, WA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (05) : 504 - 505
  • [5] Postmarketing drug surveillance: An epidemiologic approach
    Hennessy, S
    [J]. CLINICAL THERAPEUTICS, 1998, 20 : C32 - C39
  • [6] Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
    Sinaci, A. Anil
    Erturkmen, Gokce B. Laleci
    Gonul, Suat
    Yuksel, Mustafa
    Invernizzi, Paolo
    Thakrar, Bharat
    Pacaci, Anil
    Cinar, H. Alper
    Cicekli, Nihan Kesim
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [7] An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
    Misu T.
    Kortepeter C.M.
    Muñoz M.A.
    Wu E.
    Dal Pan G.J.
    [J]. Drugs - Real World Outcomes, 2018, 5 (2) : 91 - 99
  • [9] US FDA Enhancing Postmarketing Drug Safety Surveillance
    不详
    [J]. PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 64 - 64
  • [10] Intelligent Collaborative Surveillance System
    Kumar, P. N. Pavan
    Jain, Mohit
    Pavan, A.
    Bhat, M. Pramod
    Manjunath, C.
    [J]. 2013 INTERNATIONAL CONFERENCE ON ADVANCES IN TECHNOLOGY AND ENGINEERING (ICATE), 2013,